Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director

Regulations by 2FIRSTS, edited by Sophia
May.06.2024
Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Recent announcements from Jinjia Corporation (002191) reveal lifted restrictions on Qiao Luyu but investigation and detention of Li Dehua.

Recently, listed company Jinjia Group (002191) on the Shenzhen Stock Exchange has issued a series of announcements. Firstly, the disciplinary commission in Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Secondly, the company's director and deputy general manager, Li Dehua, has been placed under investigation and detained.

 

According to relevant documents issued by the Supervision Committee of Enyang District, Bazhong City, the actual controller and chairman of the company, Qiao Luyu, is under investigation and has been placed under detention. On April 27, 2024, the company received a notice from the Supervision Committee of Enyang District, Bazhong City, lifting the detention of Qiao Luyu (Enjianjie Lutong [2024] No. 2), indicating that the Supervision Committee of Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Currently, Qiao Luyu is able to carry out his duties as the chairman and legal representative of the company as normal, and the company's director and general manager, Hou Xudong, no longer acts on behalf of the company's chairman and legal representative.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image source: Jincare Group

 

On May 1st, the company received a notification from the Jinzhou District Supervisory Committee in Dalian City regarding the investigation and detention of the company's director and deputy general manager, Li Dehua.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image Source: Jincar Group

 

Jiangjia Group stated that the company has a sound governance structure and internal control mechanism, operating in compliance with laws, regulations, and rules such as the Company Law, the Shenzhen Stock Exchange Listing Rules, the Corporate Governance Guidelines for Listed Companies, and the company's articles of association. The company has already made proper arrangements for the work related to Li Dehua, and the ongoing investigation will not have a significant impact on the company's daily operations. All production and operational activities of the company are proceeding as usual.

 

Jinjia Corporation stated that as of the date of this announcement, the company is not aware of the progress and conclusion of the investigation. The company will continue to monitor the developments of the investigation and adhere to relevant laws and regulations, fulfill its disclosure obligations in a timely manner, and alert of any related risks.

 

According to the 2023 annual report of Jinjia Group, Li Dehua was born in 1968, is of Chinese nationality, does not have permanent residency abroad, has a high school education, and has been employed by Jinjia Group since 1996. He currently serves as a director, executive deputy general manager, and general manager of the production and marketing branch of the company, as well as holding other positions such as executive director of Shenzhen Qianhai Blueberry Culture Communication Co., Ltd. In 2023, Li Dehua received a total pre-tax compensation of 2.361 million yuan from the company.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04